CorMedix Inc (CRMD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $370.64M
Last updated: Nov 17, 2026 at 11:05 AM ET
CorMedix Inc (CRMD) Stock Forecast
Analysts expect CorMedix (CRMD) to earn $0.54 per share in the fiscal year ending Dec 31, 2026, on revenue of $336.65M. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 1.50, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 50.0% |
| Buy | 3 | 50.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 81.5% and revenue estimates fall 6.1%.
- Fiscal year ending Dec 31, 2026
- $0.54
- EPS consensus, revenue $336.65M
- Fiscal year ending Dec 31, 2027
- $0.10
- EPS consensus, revenue $316.03M
- Next report
- Mar 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.54 | $0.51 to $0.59 | 4 | $336.65M | $334.06M to $344.00M | 6 |
| Dec 31, 2027 | $0.10 | -$0.10 to $0.23 | 4 | $316.03M | $282.40M to $374.57M | 6 |
Quarterly Estimates
The EPS consensus rises from -$0.17 for the quarter ending Dec 31, 2026 to -$0.01 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.17 | -$0.25 to -$0.13 | 7 | $54.47M | $50.96M to $57.49M | 7 |
| Mar 31, 2027 | -$0.01 | -$0.01 to -$0.01 | 1 | $66.91M | $66.91M to $66.91M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 3 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 10.2% from $0.49.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.54 | $0.49 | $0.50 | $0.49 | $0.49 | +11.2% |
| Fiscal year ending Dec 31, 2027 | $0.10 | $0.01 | $0.06 | $0.06 | $0.06 | +58.3% |
| Quarter ending Mar 31, 2027 | -$0.01 | -$0.02 | -$0.02 | N/A | N/A | N/A |
Frequently Asked Questions About CRMD
What is the CRMD stock forecast?
Consensus analyst estimates put CorMedix's EPS at $0.54 for the fiscal year ending Dec 31, 2026, on revenue of $336.65M. The consensus rating from 6 analysts is Buy.
How do analysts rate CRMD stock?
Of 6 analysts covering CorMedix, 3 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CRMD next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.54, with estimates from $0.51 to $0.59 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.10, with estimates from -$0.10 to $0.23 from 4 analysts.
What revenue do analysts expect from CorMedix next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $336.65M, with estimates from $334.06M to $344.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $316.03M, with estimates from $282.40M to $374.57M.
How many analysts cover CRMD?
6 analysts rate CorMedix stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CRMD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors